Investigating the Tumour Immune Response of Radiotherapy
ConditionCancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Manchester
About this trial
This study aims to investigate immune changes which occur before and following standard radiotherapy in a range of tumour types. We will collect tissue and blood samples before and after radiation treatment from participants across six cancer types: cervical, rectal, Head and Neck cancer, nodal non-Hodgkin lymphoma, cutaneous lymphoma and cutaneous squamous cell carcinoma/ basal cell carcinoma.
Eligibility criteria
Qualifiers
Histologically confirmed cancer, Stage I-IV, in one of the following: Cervical, rectal, nodal Non-Hodgkin lymphoma, cutaneous lymphoma, Head & neck cancer
Diagnostic/pre-treatment biopsy confirmed suitable for translational research *
Performance status - ECOG 0-2 (Refer to appendix 1), ECOG 3 allowed for arm F (unrelated to underlying cancer) as this group of patients often have ECOG 3 due to age and comorbidities.
Age ≥ 18; no upper age limit.
Disqualifiers
Participants deemed unsuitable for a biopsy (during or following radiotherapy) in the opinion of the treating oncologist.
Participants who have received chemotherapy within 28 days of starting radiotherapy.
Participants with intercurrent or past history of hepatitis B, C or human immunodeficiency virus infection if known. A negative test result for hepatitis B, C and HIV infection is required prior to inclusion in the study.
Trial design
Treatments tested in this trial
- Biopsy and blood sample collection
Treatment groups
120 Participants
are divided into 6 treatment groups6
Treatment groupsSee each treatment group below.
Sponsors and collaborators
University of Manchester
Lead sponsor
The Christie NHS Foundation Trust
Collaborator
Source ClinicalTrials.gov